Azithromycin use prior to ICU admission is associated with a lower short-term mortality for critically ill acute exacerbations of chronic obstructive pulmonary disease patients: A retrospective cohort study

Xuequn Guo1,*, Hongsheng Lin1,*, Donghao Guo2 and Qiu Luo3

Abstract
Azithromycin was thought to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD) by antimicrobial and anti-inflammatory effects. However, its value in the treatment of critically ill patients with AECOPD before ICU admission remains unclear. Our study aimed to find whether azithromycin use prior to ICU admission leads to better clinical outcomes for those individuals. 533 critically ill patients with AECOPD from the MIMIC-IV database were included. Univariate followed multivariate logistic regression was used to select risk factors for short-term mortality. The multivariable logistic regression models were implemented to investigate the association between azithromycin use before ICU admission and short-term mortality. Lower short-term mortality was observed in the azithromycin group (p = .021), independent of differences in demographic data and other clinical outcomes (p > .05). Azithromycin use before ICU admission was proved to have a decreased short-term mortality by multivariable logistic regression (p < .05). The results remained consistent after being stratified by age, SOFA scores, pH, and cancer diagnosis. Azithromycin use prior to ICU admission was associated with lower short-term mortality for critically ill AECOPD patients.

Keywords
acute exacerbations of chronic obstructive pulmonary disease, azithromycin, critical care, intensive care unit, short-term mortality

Background
Chronic obstructive pulmonary disease (COPD) is still the third leading cause of death and disability worldwide, with an estimated medical cost of $36 billion annually in the United States.1–4 Up to 60% of these costs are attributed to acute exacerbations of COPD (AECOPD), which could bring negative effects on health status, quality of life, and hospitalization rates.1,4–6 When AECOPD is evaluated as life-threatening based on clinical presentations, further treatment in the intensive care unit (ICU) will be necessary.1,7 However, despite advances in medical care,
the mortality of these patients remains high.\(^8\)\(^,\)\(^9\) Therefore, establishing an appropriate treatment regimen for critically ill patients with AECOPD is a high priority.

As a kind of macrolide antibiotic, azithromycin, with potent antimicrobial and immunomodulatory effects, was proved to bring large clinical benefits to COPD patients.\(^10\)\(^-\)\(^12\) After repeated validation, long-term use of azithromycin has been established to prevent AECOPD for patients with COPD and was included in authoritative guidelines.\(^1\)\(^,\)\(^13\)\(^,\)\(^14\) However, it remains controversial whether azithromycin should be routinely used at the beginning of AECOPD, especially for the severe ones requiring critical care in ICU, where azithromycin is often considered to be of limited benefit.\(^1\)\(^,\)\(^11\)\(^,\)\(^12\) To address this question, we conducted this study to evaluate whether azithromycin use prior to ICU admission could provide better clinical benefits for critically ill patients with AECOPD.

**Methods**

**Data source**

All data were obtained from the Medical Information Mart for Intensive Care IV (MIMIC IV) open-source clinical database (version 1.0), which contains information for more than 50,000 patients who were admitted to the intensive care unit (ICU) of the Beth Israel Deaconess Medical Center during 2008 to 2019.\(^15\)\(^,\)\(^16\) One author was obliged to complete the online course and pass the online exams to gain access to the database (Xuequn, Certification number: 35,875,386) after signing a data use agreement (https://physionet.org/content/mimiciv/view-dua/1.0/). Owing to all the data in the database being anonymous, the informed consent for the individual was not required.

**Cohort selection**

Our inclusion criteria were as follows: (1) Patients were older than 18 years and stayed in the ICU for more than 24 hours; (2) Patients were diagnosed as AECOPD by ICD-10 code\(^17\)\(^-\)\(^19\) on admission; (3) To ensure that patients were admitted to ICU because of AECOPD, combined type II respiratory failure was set as an inclusion criterion. Type II respiratory failure is defined by the max partial pressure of carbon dioxide (\(\text{PaCO}_2\)) > 45 mmHg (6 kPa) and the min pH < 7.35 within 12 hours before ICU admission.\(^20\) Exclusion criteria are surgically related complications like severe trauma, burns and vital organ surgery. The primary outcome was short-term (30 days) mortality. Only the data from the first hospital and the first ICU admission was retained (Figure 1).

**Statistical analysis**

SKTEST order was run in STATA (Skewness and kurtosis tests for normality), which presents a test for normality based on skewness and another based on kurtosis and then combines the two tests into an overall test statistic, to validate the variables to assess whether they fit normal distribution. Then, continuous data were presented in the tables as the mean with standard deviation (normal distribution) or median with interquartile
ranges (non-normal distribution) and compared by Student t-test (normal distribution) or Wilcoxon rank-sum test (non-normal distribution). Categorical data were presented as percentages, while the significance of the differences was determined through Chi-squared test. Univariate followed stepwise back multivariate logistic regression was used to identify the risk factors for short-term death. Multivariate logistic analysis with complex models adjusted for risk factors selected above was employed to investigate the independent effects of azithromycin use before ICU admission on short-term mortality. The complex models were as follows: no adjustment (Model1), adjusted for age (Model 2), adjusted for and SOFA scores (Model 3); adjusted for age, SOFA scores and pH (Model 4); adjusted for age, SOFA scores, pH and diagnosis of cancer (Model 5).

Variance inflation factor (VIF) was taken to test collinearity between continuous variables, and VIF ≤ 5 was seen as non-collinearity. Stata 15.1 software (Stata-Corp, Texas, USA) and R software (version 4.0.0, www.r-project.org) was implemented for the statistical analysis, and p < .05 was considered statistically significant.

Results

After execution of inclusion and exclusion criteria, data of 533 critically ill AECOPD patients with hypercapnic respiratory failure were included in the final cohort, including 445 survivors and 88 non-survivors, spelling overall short-term mortality of 16.5% (Table 1). Among these patients, 94 had received azithromycin before ICU admission, 197 had received azithromycin after ICU admission, and 47 had both. As the ATS guidelines recommending the use of macrolides for the prevention of AECOPD were published in 2017,22 we analyzed the proportion of patients using azithromycin pre- and post- 2017. However, no significant difference was observed (p = .55). Compared to the survival group, the non-survival group held older age (p = .002) and higher SOFA scores (p < .001). Differences in pH (p < .001) were observed at admission. When it came to pre-ICU treatment, only azithromycin was found to be statistically different between the survival and non-survival groups (p = .021). Notably, when we retained only patients who used azithromycin before ICU admission, the total times of azithromycin use (p = .577) and the total dose of azithromycin use (p = .231) did not differ between the survival and non-survival groups. In addition, azithromycin use after ICU admission had no effect on short-term death. Then, Samples were divided into two groups based on whether azithromycin was used prior to ICU admission as shown in Table2, including 94 samples who received azithromycin before admission to ICU and 439 who did not. No significant differences in age, gender, BMI, ethnicity or SOFA scores were observed between the azithromycin and non-azithromycin groups, the same to blood gas results (p > .05). Regarding treatments, the ratio of non-invasive ventilator use and invasive ventilator use did not differ between the two groups (p = .005). As for clinical outcomes, a lower short-term mortality (non-A vs A = 18.2 vs 8.2%) was observed in the azithromycin group, without difference in long-term mortality (non-A vs A = 18.9 vs 11.7%), length of hospital stay (non-A vs A = 9 vs 10 days), and length of ICU stay (non-A vs A = 4 vs 3 days).

Univariate followed multivariate analysis indicated that age (p < .001), SOFA score (p < .001), pH (p = .022) and cancer (p = 0.001) were independent predictors for short-term mortality, with no association existing in dosage and frequency of azithromycin before admission to ICU, other antibiotics use before ICU admission and some other comorbidities (p > .05), as shown in Table 3. After adjusting for predictors above individually or together (Model1 = No adjust; Model2 = Adjust for Age; Model3 = Model2 + SOFA; Model4 = Model3 + pH; Model5 = Model4 + cancer), multivariate logical analyses demonstrated that non-azithromycin use before ICU admission was an independent risk factor for short-term mortality (Model1 OR = 0.42, 95% CI 0.19–0.90; Model2 OR = 0.41, 95% CI 0.19–0.88; Model3 OR = 0.44, 95% CI 0.20–0.95; Model4 OR = 0.41, 95% CI 0.19–0.91; Model4 OR = 0.41, 95% CI 0.18–0.92, Table 4).

Discussion

Our study showed that critically ill ACOPD patients who received azithromycin prior to ICU admission had a lower short-term mortality rate. This association was independent of the dose or times of azithromycin use and other antibiotic use before ICU admission. To our knowledge, the present study is the first time for this view to be suggested.

Despite progress in treatment, poor prognosis, including declining lung function, poorer quality of life and increased risk of mortality, is commonly seen in AECOPD patients when they are identified as life-threatening exacerbations.1,5,6 Thus, the critical care in ICU is required for these patients. A meta-analysis focusing on AECOPD patients admitted to ICU showed mortality for the collective was extremely high, reaching 17.6%–48.8% during hospitalization.7 Another study with a similar subject gave a mortality rate as high as 27%.23 All suggested that treatment for AECOPD patients requiring ICU admission is particularly important.

AECOPD, arousing by various infectious and noninfectious stimuli, was usually accompanied by higher inflammation status from the very beginning, making early identification and management of AECOPD meaningful in clinical practice.24,25 Research has shown that this series of inflammatory responses are not limited to lungs, but occurs throughout the body.26 Despite the exact mechanism remains unclear, some inflammatory factors, like CRP,
Interleukin-6 (IL-6), interleukin-8 (IL-8), leukotriene B4 (LTB4), and tumor necrosis factor-α (TNF-α), were discovered to be associated with occurrence and prognosis of AECOPD.27,28 This may be the root cause of the positive effect of corticosteroids and other anti-inflammatory drugs on the short-term recovery of symptoms and long-term clinical outcomes of AECOPD patients.1,29–31

Azithromycin, as a kind of macrolide, with both anti-microbial and anti-inflammatory effects, has repeatedly been proved to have significant effects on chronic inflammation.11–13 In the anti-microbial aspect, azithromycin has a wide spectrum, which has a strong anti-bacterial effect on not only Gram-positive bacteria, but also some Gram-negative bacteria, mycoplasma, chlamydia and

Table 1. Comparisons of demographics between survivors and non-survivors.

| Demographics                     | Survivors (n = 445) | Non-survivors (n = 88) | p value |
|----------------------------------|--------------------|------------------------|---------|
| Age (years±SD.)                  | 71.4±10.3          | 75.2±10.3              | 0.002   |
| Male (n%)                        | 219 (48.1)         | 43 (57.9)              | 0.952   |
| BMI(kg/m²±SD.)                   | 29.4±8.6           | 27.5±8.0               | 0.053   |
| Ethnicity (n%)                   |                    |                        |         |
| white                            | 297 (65.3)         | 51 (57.9)              | 0.255   |
| black                            | 31 (6.8)           | 2 (2.3)                |         |
| asian                            | 11 (2.4)           | 2 (2.3)                |         |
| others                           | 106 (23.3)         | 33 (37.5)              |         |
| SOFA (IQR)                       | 6 (4–8)            | 8 (5–11)               | <0.001  |
| Blood gas at ICU admission       |                    |                        |         |
| pH(IQR)                          | 7.28 (7.22–7.34)   | 7.24 (7.16–7.32)       | <0.001  |
| PaO2(mmHg,IQR)                   | 50 (37–71)         | 44 (34–69)             | 0.341   |
| PaCO2(mmHg,IQR)                  | 62 (52–79)         | 66 (57–83)             | 0.071   |
| FiO2 (%IQR)                      | 50 (40–80)         | 55 (40–100)            | 0.095   |
| PaO2/FiO2 (mmHg, IQR)            | 109 (72–162)       | 94 (59–151)            | 0.097   |
| Comorbidities (n%)               |                    |                        |         |
| Congestive heart failure         | 213 (46.8)         | 44 (50.0)              | 0.714   |
| Myocardial infarction            | 101 (22.2)         | 19 (21.6)              | 0.820   |
| Hypertension                     | 86 (18.9)          | 19 (21.6)              | 0.625   |
| Cerebrovascular disease          | 37 (8.1)           | 7 (7.9)                | 0.911   |
| Diabetes                         | 134 (29.5)         | 22 (25.0)              | 0.229   |
| Renal disease                    | 97 (21.3)          | 16 (18.2)              | 0.448   |
| Treatments                       |                    |                        |         |
| Azithromycin before ICU admission (n%) | 86 (19.3)   | 8 (9.1)                | 0.021   |
| Total times of azithromycin before ICU admission (only for the azithromycin group; times, IQR) | 1 (1–2) | 1 (1–2) | 0.577 |
| Total dose of azithromycin before ICU admission (only for the azithromycin group; mg, IQR) | 500 (250–500) | 500 (375–875) | 0.231 |
| Azithromycin after ICU admission (n%) | 164 (36.9) | 33 (37.5) | 0.909 |
| Azithromycin before and after ICU admission (n%) | 39 (8.8) | 8 (9.1) | 0.921 |
| Penicillins before ICU admission (n%) | 52 (11.7) | 7 (7.9) | 0.308 |
| Cephalosporin before ICU admission (n%) | 129 (28.9) | 19 (21.6) | 0.157 |
| Quinolone before ICU admission (n%) | 67 (15.1) | 14 (15.6) | 0.839 |
| Vancomycin before ICU admission (n%) | 16 (3.6) | 2 (2.3) | 0.746 |
| Carbapenems before ICU admission (n%) | 114 (25.6) | 23 (26.1) | 0.826 |
| Non-invasive ventilator use (n%) | 196 (44.0) | 31 (35.2) | 0.126 |
| Invasive ventilator use (n%)     | 240 (53.9)         | 55 (62.5)              | 0.140   |

Continuous data are presented as mean ± standard deviation (SD) or median (interquartile ranges), and categorical data are presented as frequency (percentage).

Abbreviations: BMI, body mass index; SOFA, Sequential organ failure assessment; pH, potential of Hydrogen; PaO2, partial pressure of oxygen; PaCO2, partial pressure of carbon dioxide; FiO2, fraction of inspiration oxygen; IQR, interquartile ranges.
legionella. In the meantime, there is a post antimicrobial effect of azithromycin. After drug withdrawal, the concentration of the drug released in the cell still exceeds the minimum inhibitory concentration of common sensitive bacteria within 5–7 days. Azithromycin is often recommended for ACOPD patients with infective evidence but milder illness state and fewer comorbidities during acute exacerbation periods. For AECOPD patients evaluated as life-threatening, labeled older age, more severe state and more comorbidities, azithromycin is not the first choice and early combination with other antibiotics is not recommended. In addition to the coverage for common pathogenic bacteria of lung infection in AECOPD patients, azithromycin, like other macrolides, are involved in multiple anti-inflammatory activities, including suppression of some pro-inflammatory cytokines, attenuated chemotaxis and adhesion of neutrophils, hypoactive proliferation of monocytes, enhanced phagocytosis of apoptotic cells, alleviation of oxidant burst, reduction of mucus secretion, inhibition of angiogenesis, and decrease of virulence factors. Besides, azithromycin may join the response to corticosteroids by enhancing the recruitment of histone deacetylase 2, which is seen as a major contributor to the inflammatory gene repression produced by corticosteroids in patients with COPD, thus resulting in less corticosteroid use. Based on this anti-inflammatory effect, several studies suggested chronic azithromycin in COPD patients to prevent AECOPD. Numerous controlled trials implied inclusion of azithromycin in the treatment regimen may bring clinical benefits for critically ill patients with AECOPD, including reductions in hospital readmissions, improvements in time to next readmission and decrease of ICU costs. In a study involving more than 25,000 patients with AECOPD admitted to the ICU, macrolides initiated within 2 days of admission reduced hospital costs and 30-days ICU readmission rates. Azithromycin is also used in other ICU conditions due to its antibacterial and anti-inflammatory effects. Afshar et al. found that azithromycin was associated with less ICU stay days in severe sepsis patients received mechanical ventilation. Another study showed macrolide antibiotics could decreased death risk from septic shock and multiple organ dysfunctions for severe sepsis patients with ventilator-associated pneumonia.

There were several limitations to our study. For one thing, as a retrospective study, all our data is based on the MIMIC-IV databases. Although the sample size of our study was not small, future larger multicenter prospective studies are warranted to further validate our points. For another, in order to ensure that the extracted data were admitted to ICU because of AECOPD, we only selected patients with type II respiratory failure, which would inevitably lead to selection bias. Additionally, the use of azithromycin may simply be a surrogate marker for an unknown confounder, such as access to a primary care

| Table 2. Comparisons of population information and clinical outcomes between Azithromycin and Non-Azithromycin groups. |
|---------------------------------------------------------------|
| Variable | Non-azithromycin before ICU admission (n = 439) | Azithromycin before ICU admission (n = 94) | p value |
|---------------------------------------------------------------|
| Demographics | | | |
| Age (years±SD.) | 72±10 | 72±11 | 0.971 |
| Male (n%) | 217 (49.4) | 45 (47.9) | 0.784 |
| BMI(kg/m2±SD.) | 28.9±8.6 | 29.5±8.3 | 0.545 |
| Ethnicity (n%) | | | |
| White | 287 (65.4) | 61 (64.9) | 0.489 |
| Black | 20 (4.6) | 13 (13.8) | 0.362 |
| Asian | 10 (2.3) | 3 (3.2) | |
| Others | 122 (27.8) | 17 (18.1) | |
| SOFA (IQR) | 6 (4–9) | 6 (4–8) | 0.482 |
| Clinical outcomes | | | |
| Short-term death (n%) | 80 (18.2) | 8 (8.5) | 0.021 |
| Long-term death (n%) | 83 (18.9) | 11 (11.7) | 0.096 |
| Hospital duration (days,IQR) | 9 (6–17) | 10 (6–16) | 0.975 |
| ICU duration (days,IQR) | 4 (2–7) | 3 (2–6) | 0.358 |
| Non-invasive ventilator use (n%) | 183 (41.7) | 44 (46.8) | 0.362 |
| Invasive ventilator use (n%) | 248 (56.5) | 47 (50.0) | 0.251 |

Continuous data are presented as mean ± standard deviation (SD) or median (interquartile ranges), and categorical data are presented as frequency (percentage).

Abbreviations: BMI, body mass index; SOFA, Sequential organ failure assessment; IQR, interquartile ranges.
physician, a respirology/pulmonology specialist, and/or medicare, causing confounding bias. Furthermore, the absence of data on whether patients used azithromycin before admission will lead to a decrease in persuasiveness.

### Conclusion

Azithromycin use prior to ICU admission was associated with lower short-term mortality for critically ill AECOPD patients, the correlation was independent of the dose and times of azithromycin use. Therefore, we recommend the routine use of azithromycin for AECOPD patients who are admitted to the emergency department in serious conditions or whose condition changes during hospitalization and may require further treatment in ICU.

#### Table 3. Univariate and multivariate logistic analysis of variables and short-term mortality.

| Variable                                | Univariate logistic analysis | Multivariate logistic analysis |
|-----------------------------------------|------------------------------|-------------------------------|
|                                         | OR (95% CI)                  | p value                       | OR (95% CI)                  | p value                       |
| Age                                     | 1.04 (1.01–1.06)             | 0.002                         | 1.05 (1.02–1.07)             | <0.001                        |
| Male                                    | 0.99 (0.62–1.56)             | 0.952                         |                              |                              |
| BMI                                      | 0.97 (0.94–1.00)             | 0.054                         |                              |                              |
| Ethnicity                               | 0.93 (0.68–1.27)             | 0.660                         |                              |                              |
| SOFA                                    | 1.15 (1.09–1.23)             | <0.001                        | 1.14 (1.07–1.22)             | <0.001                        |
| pH                                      | 0.01 (0.00–0.08)             | <0.001                        | 0.04 (0.01–0.64)             | 0.022                         |
| PaO2                                    | 1.00 (0.99–1.01)             | 0.782                         |                              |                              |
| PaCO2                                   | 1.01 (0.99–1.02)             | 0.125                         |                              |                              |
| FiO2                                    | 1.01 (0.99–1.02)             | 0.107                         |                              |                              |
| PaO2/FiO2                                | 0.99 (0.99–1.00)             | 0.800                         |                              |                              |
| Congestive heart failure                 | 1.09 (0.69–1.72)             | 0.714                         |                              |                              |
| Myocardial infarction                    | 0.94 (0.54–1.63)             | 0.821                         |                              |                              |
| Hypertension                            | 0.94 (0.57–1.53)             | 0.793                         |                              |                              |
| Cerebrovascular disease                  | 0.95 (0.41–2.21)             | 0.911                         |                              |                              |
| Diabetes                                | 0.77 (0.46–1.31)             | 0.336                         |                              |                              |
| Renal disease                           | 0.80 (0.44–1.43)             | 0.449                         |                              |                              |
| Cancer                                  | 2.08 (1.16–3.73)             | 0.014                         | 2.83 (1.51–5.29)             | 0.001                         |
| Azithromycin before ICU admission        | 0.42 (0.19–0.90)             | 0.025                         | 0.41 (0.18–0.92)             | 0.030                         |
| Total times of azithromycin before ICU admission (only for the azithromycin group) | 0.63 (0.37–1.06) | 0.081 |                              |                              |
| Total dose of azithromycin before ICU admission (only for the azithromycin group) | 1.00 (0.99–1.00) | 0.211 |                              |                              |
| Penicillins before ICU admission         | 0.65 (0.29–1.49)             | 0.311                         |                              |                              |
| Cephalosporin before ICU admission       | 0.67 (0.39–1.17)             | 0.159                         |                              |                              |
| Quinolone before ICU admission           | 1.07 (0.57–1.99)             | 0.839                         |                              |                              |
| Vancomycin before ICU admission          | 0.62 (0.14–2.76)             | 0.534                         |                              |                              |
| Carbapenems before ICU admission         | 1.03 (0.61–1.73)             | 0.919                         |                              |                              |
| Non-invasive ventilator use              | 0.69 (0.43–1.11)             | 0.128                         |                              |                              |
| Invasive ventilator use                  | 1.42 (0.89–2.82)             | 0.141                         |                              |                              |

Abbreviations: OR, odd ratio; CI, confidence interval; BMI, body mass index; SOFA, Sequential organ failure assessment; pH, potential of Hydrogen; PaO2, partial pressure of oxygen; PaCO2, partial pressure of carbon dioxide; FiO2, fraction of inspiration oxygen; IQR, interquartile ranges.

#### Table 4. ORs associated with azithromycin before ICU admission and short-term mortality by multiple regression models.

| Multiple regression models | OR (95% CI) | p value |
|----------------------------|-------------|---------|
| Model1                     | 0.42 (0.19–0.90) | 0.025   |
| Model2                     | 0.41 (0.19–0.88) | 0.023   |
| Model3                     | 0.44 (0.20–0.95) | 0.037   |
| Model4                     | 0.41 (0.19–0.91) | 0.028   |
| Model5                     | 0.41 (0.18–0.92) | 0.030   |

Adjusted covariates: Model1 = No adjust; Model2 = Adjust for Age; Model3 = Model2 + SOFA; Model4 = Model3 + pH; Model5 = Model4 + cancer.

Abbreviations: OR, odd ratio; CI, confidence interval; SOFA, Sequential organ failure assessment; pH, potential of Hydrogen.
Authors contributions

XG: Responsible for data extraction and writing of the manuscript. HL: Responsible for data analysis and data validation. DG: Participate in data validation and proofreading of the manuscript. QL: Responsible for proofreading of the manuscript. XG and HL contributed equally to this manuscript. All authors read and approved the final manuscript.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The MIMIC database was supported by grants from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health (NIH) under award numbers R01-EB001659 (2003–2013) and R01-EB017205 (2014–2018).

Ethics approval and consent to participate

The project was approved by the review boards of the Massachusetts Institute of Technology and Beth Israel Deaconess Medical Center. There was no requirement of individual informed consent to extract data from the MIMIC-IV database because data from this database was publicly available and information of all patient were de-identified.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

ORCID iD

Xuequn Guo https://orcid.org/0000-0002-7677-7815
Hongsheng Lin https://orcid.org/0000-0003-4937-5148
Donghao Guo https://orcid.org/0000-0002-8300-8176
Qiu Luo https://orcid.org/0000-0002-4565-3270

References

1. Halpin DMG, Criner GJ, Papi A, et al. Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2021; 203(1): 24–36.
2. Lopez-Campos JL, Tan W and Soriano JB. Global burden of COPD. Respirology 2016; 21(1): 14–23.
3. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. The Lancet 2007; 370(9589): 741–750.
4. Ford ES, Murphy LB, Khavjou O, et al. Total and state-specific medical and absenteeism costs of COPD among adults aged >/= 18 years in the United States for 2010 and projections through 2020. Chest 2015; 147(1): 31–45.
5. Wedzicha JA and Seemungal TAR. COPD exacerbations: defining their cause and prevention. The Lancet 2007; 370(9589): 786–796.
6. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157(5 Pt 1): 1418–1422.
7. Celli BR, MacNee W and Force AET. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23(6): 932–946.
8. Batzlauff CM, Karpman C, Afessa B, et al. Predicting 1-year mortality rate for patients admitted with an acute exacerbation of chronic obstructive pulmonary disease to an intensive care unit: an opportunity for palliative care. Mayo Clin Proc 2014; 89(5): 638–643.
9. Singanayagam A, Schernbi S and Chalmers JD. Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc 2013; 10(2): 81–89.
10. Martinez FJ, Curtis JL and Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. J Chron Obstruct Pulmon Dis 2008; 3(3): 331–350.
11. Kiser TH, Reynolds PM, Moss M, et al. Impact of macrolide antibiotics on hospital readmissions and other clinically important outcomes in critically ill patients with acute exacerbations of chronic obstructive pulmonary disease: a propensity score-matched cohort study. Pharmacotherapy 2019; 39(3): 242–252.
12. Shryock TR, Mortensen JE and Baumholtz M. The effects of macrolides on the expression of bacterial virulence mechanisms. J Antimicrob Chemother 1998; 41(5): 505–512.
13. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365(8): 689–698.
14. Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med 2014; 189(12): 1503–1508.
15. Johnson A B L, Pollard T., Horng S.et al. MIMIC-IV (Version 1.0). PhysioNet. https://doi.org/10.13026/s6m6-xd98, 2021.
16. Goldberger AL, Amaral LA, Glass L, et al. Physio bank, physio toolkit, and physionet: components of a new research resource for complex physiologic signals. Circulation 2000; 101(23): E215–E220.
17. The L. ICD-10: there’s a code for that. The Lancet 2015; 386(10002): 1420.
18. Johnson AE, Stone DJ, Celi LA, et al. The MIMIC code repository: enabling reproducibility in critical care research. J Am Med Inform Assoc 2018; 25(1): 32–39.
19. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care* 2005; 43(11): 1130–1139.

20. Ding M, Han X, Bai L, et al. Impact of HACOR score on noninvasive ventilation failure in non-COPD patients with acute-on-chronic respiratory failure. *Can Respir J* 2021; 2021: 9960667.

21. Marcoulides KM and Raykov T. Evaluation of variance inflation factors in regression models using latent variable modeling methods. *Educ Psychol Meas* 2019; 79(5): 874–882.

22. Wedzicha JA, Calverley PMA, Albert RK, et al. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. *Eur Respir J* 2017; 50(3): 1602265.

23. Stolz D, Barandun J, Borer H, et al. Diagnosis, prevention and treatment of stable COPD and acute exacerbations of COPD: the swiss recommendations 2018. *Respiration* 2018; 96(4): 382–398.

24. Fu JJ, McDonald VM, Baines KJ, et al. Airway IL-1beta and systemic inflammation as predictors of future exacerbation risk in asthma and COPD. *Chest* 2015; 148(3): 618–629.

25. Rodrigues F, Papoila AL, Ligeiro D, et al. Acute exercise amplifies inflammation in obese patients with COPD. *Rev Port Pneumol* 2006 2016; 22(6): 315–322.

26. De Backer J, Vos W, Van Holsbeke C, et al. Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. *Int J Chron Obstruct Pulmon Dis* 2013; 8: 569–579.

27. Corsonello A, Pedone C, Battaglia S, et al. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) as inflammation markers in elderly patients with stable chronic obstructive pulmonary disease (COPD). *Arch Gerontol Geriatr* 2011; 53(2): 190–195.

28. Zeng YY, Hu WP, Zuo YH, et al. Altered serum levels of type 1 collagen turnover indicators accompanied by IL-6 and IL-8 release in stable COPD. *Int J Chron Obstruct Pulmon Dis* 2019; 14: 163–168.

29. Scholl T, Kiser TH and Vondracek SF. Evaluation of systemic corticosteroids in patients with an acute exacerbation of COPD and a diagnosis of pneumonia. *Chronic Obstr Pulm Dis* 2018; 5(1): 57–65.

30. Kiser TH, Allen RR, Valuck RJ, et al. Outcomes associated with corticosteroid dosage in critically ill patients with acute exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2014; 189(9): 1052–1064.

31. Ali A, de la Cal MA, Esteban A, et al. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. *Arch Intern Med* 2011; 171(2): 1939–1946.

32. Hirsch R, Deng H and Laohachai MN. Azithromycin in periodontal treatment: more than an antibiotic. *J Periodontal Res* 2012; 47(2): 137–148.

33. Amsden G. Erythromycin, clarithromycin, and azithromycin: are the differences real? *Clin Ther* 1996; 18(1): 56–72.

34. Al-Hasan MN and Al-Jagheer MJ. Use of antibiotics in chronic obstructive pulmonary disease: what is their current role in older patients? *Drugs Aging* 2020; 37(9): 627–633.

35. Ko FW, Chan KP, Hui DS, et al. Acute exacerbation of COPD. *Respirology* 2016; 21(7): 1152–1165.

36. Huang L, Wang J, Gu X, et al. Procalcitonin-guided initiation of antibiotics in AECOPD inpatients: study protocol for a multicenter randomised controlled trial. *BMJ Open* 2021; 11(8): e049515.

37. Crisafulli E, Barbeta E, Ielpo A, et al. Management of severe acute exacerbations of COPD: an updated narrative review. *Multidiscip Respir Med* 2018; 13: 36.

38. Wozniak DJ and Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. *Chest* 2004; 125(2 Suppl): 62S–69S. quiz 69S.

39. Hodge S, Hodge G, Jersmann H, et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2008; 178(2): 139–148.

40. Cramer CL, Patterson A, Alchakaki A, et al. Immunomodulatory indications of azithromycin in respiratory disease: a concise review for the clinician. *Postgrad Med* 2017; 129(5): 493–499.

41. Amsden GW. Anti-inflammatory effects of macrolides—an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? *J Antimicrob Chemother* 2005; 55(1): 10–21.

42. Healy DP. Macrolide immunomodulation of chronic respiratory diseases. *Curr Infect Dis Rep* 2007; 9(1): 7–13.

43. Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. *J Allergy Clin Immunol* 2013; 131(3): 636–645.

44. Taylor SP, Sellers E and Taylor BT. Azithromycin for the treatment of stable COPD and acute exacerbations of COPD: a concise review for the clinician. *Postgrad Med* 2017; 129(5): 493–499.

45. Amsden GW. Anti-inflammatory effects of macrolides—an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? *J Antimicrob Chemother* 2005; 55(1): 10–21.

46. Healy DP. Macrolide immunomodulation of chronic respiratory diseases. *Curr Infect Dis Rep* 2007; 9(1): 7–13.

47. Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. *J Allergy Clin Immunol* 2013; 131(3): 636–645.

48. Taylor SP, Sellers E and Taylor BT. Azithromycin for the prevention of COPD exacerbations: the good, bad, and ugly. *Am J Med* 2015; 128(12): 1362–1366.

49. Vermeersch K, Gabrovsk M, Aumann J, et al. Azithromycin during acute chronic obstructive pulmonary disease exacerbations requiring hospitalization (BACE). A multicenter, randomized, double-blind, placebo-controlled trial. *Am J Respir Crit Care Med* 2019; 200(7): 857–868.

50. Baalhaki N, Giuliani C, Hartner CL, et al. Azithromycin versus beta-lactams in hospitalized patients with acute exacerbations of COPD. *J Gen Intern Med* 2022; Mar 22: 1–6.

51. Afshar M, Foster CL, Layden JE, et al. Azithromycin use and outcomes in severe sepsis patients with and without pneumonia. *J Crit Care* 2016; 32: 120–125.

52. Spyridaki A, Raftogiannis M, Antonopoulou A, et al. Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. *Antimicrob Agents Chemother* 2012; 56(7): 3819–3825.